With a strong team in place, Earth Science Tech, Inc. (OTC: ETST) is well on its way to becoming a licensed distributor and bringing its products to the Canadian marketplace. Discussing the company’s strong team and positioning in the sector, ETST CEO and CSO Dr. Michel Aube stated in a news release, “We have all of the knowledge, experience and proficiency that we need to bring our products to the marketplace and become a licensed distributor of drugs and controlled substances in Canada, as announced earlier this year.” An article discussing the company reads: “The company has already received a grant through Canna Inno Laboratories Inc. from the Government of Québec to support the pre-launch process of three CBD-based products that aim to prevent common causes of cancer and help reduce occurrence rates. ETST is strategically working to improve treatments for different diseases on a global scale. Human clinical trials are set to begin in 2019, or later, in producing an over-the-counter (OTC) drug and a cannabinoid companion generic drug that battles opioid dependency. ETST is planning to investigate the synergies between mineral elements and cannabinoid industrial hemp oil. This could potentially be used as a treatment for opioid dependency.”
To view the full article, visit http://ibn.fm/Tj6gP
About Earth Science Tech, Inc.
Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil. For more information, visit the company’s website at www.EarthScienceTech.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
